Comparison of PET/CT with ⁶⁸Ga-FAPI-04 and ⁶⁸Ga-FAP-2286 in vivo for inflammatory and oncological diseases. Clinical cases

Purpose: To study the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 in oncological and inflammatory diseases and to compare the diagnostic capabilities of ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04, including in the context of its potential use for patient selection for 177Lu‑FAP‑2286 radionuclide therapy. Material and methods: PET/CT studies with ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04 were performed on two patients: one with an oncological disease and one with an inflammatory process. The ⁶⁸Ga‑FAP‑2286 PET/CT scan was conducted in three phases — at 5 minutes, 60 minutes, and 180 minutes after radiopharmaceutical administration, followed by an assessment of the dynamics of SUV_max changes in the target regions. PET/CT scanning with ⁶⁸Ga‑FAPI‑04 was performed in a single step, 60 minutes post‑injection Conclusion: ⁶⁸Ga‑FAPI‑04 and ⁶⁸Ga‑FAP‑2286 have similar diagnostic characteristics. Differences in the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 between tumorous and inflammatory changes were also identified.

1. Belkin EV, Tulin PE, Abu‑Khaydar OB. PET/CT with ⁶⁸Ga‑FAPI and 18F‑FDG in the Detection of Metastases in Regional Lymph Nodes in Gastric Cancer. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2025;8(1):29‑35. (In Russ.). https://doi.org/10.37174/2587‑7593‑2025‑8‑1‑29‑35

2. Tulin PE, Polyakov AN, Pronin AI. PET/CT with ⁶⁸Ga‑FAPI in the Diagnosis of Cancer of Unknown Primary Localization. Clinical Case. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2023;6(4):99‑104. (In Russ.). https://doi.org/10.37174/2587‑7593‑2023‑6‑4‑99‑104

3. Wang H, Zhu W, Ren S, et al. ⁶⁸Ga‑FAPI‑04 versus 18F‑FDG PET/CT in the detection of hepatocellular carcinoma. Frontiers in Oncology, 11, 2021;693640. https://doi.org/10.3389/fonc.2021.693640

4. Elboga U, Sahin E, Kus T, et al. Superiority of ⁶⁸Ga‑FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Annals of Nuclear Medicine 35, 2021;1321‑31. https://doi.org/10.1007/s12149‑021‑01672‑x

5. Kessler L, Hirmas N, Pabst KM, et al. ⁶⁸Ga‑Labeled fibroblast activation protein inhibitor (⁶⁸Ga‑FAPI) PET for pancreatic adenocarcinoma: data from the ⁶⁸Ga‑FAPI PET observational trial. Journal of Nuclear Medicine, 2023;64(12):1910‑17. https://doi.org/10.2967/jnumed.122.264827

6. Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein–targeted radiotracers with improved tumor retention. Journal of Nuclear Medicine, 2019;60(10):1421‑9. https://doi.org/10.2967/jnumed.118.224469

7. Fu K, Pang Y, Zhao L, et al. FAP‑targeted radionuclide therapy with [177Lu]Lu‑FAPI‑46 in metastatic nasopharyngeal carcinoma. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;1767‑9 https://doi.org/10.1007/s00259‑021‑05634‑3

8. Zboralski D, Hoehne A, Bredenbeck A, et al. Preclinical evaluation of FAP‑2286 for fibroblast activation protein targeted radionuclide imaging and therapy. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;3651‑67. https://doi.org/10.1007/s00259‑022‑05842‑5

9. Yizhen P, Liang Zh, Tinghua M, et al. Journal of Nuclear Medicine, 2023;64 (3):386‑94. https://doi.org/10.2967/jnumed.122.264544

10. Kline B, Yadav S, Seo Y, et al. ⁶⁸Ga‑FAP‑2286 PET of Solid Tumors: Bio‑ distribution, Dosimetry, and Comparison with 18F‑FDG. Journal of Nuclear Medicine, 2024;65(6):938‑943. https://doi.org/10.2967/jnumed.123.267281; PMID: 38697672; PMCID: PMC11149593

11. Pang Y, Zhao L, Meng T, et al. PET imaging of fibroblast activation protein in various types of cancer using ⁶⁸Ga‑FAP‑2286: comparison with 18F‑FDG and ⁶⁸Ga‑FAPI‑46 in a single‑center, prospective study. Journal of Nuclear Medicine, 2023;64(3):386‑94. https://doi.org/10.2967/jnumed.122.264544

12.